US 11,939,361 B2
Compositions of peptide inhibitors of Interleukin-23 receptor
Giustino Di Pretoro, Beerse (BE); Dajun Sun, Beerse (BE); Gopal Rajan, Beerse (BE); Geraldine Broeckx, Beerse (BE); Nathalie Mertens, Beerse (BE); Shu Li, Newark, CA (US); Felix Lai, Newark, CA (US); Mohammad Masjedizadeh, Newark, CA (US); Anne M. Fourie, San Diego, CA (US); Beverly Knight, San Diego, CA (US); David Polidori, Rancho Santa Fe, CA (US); Santhosh Francis Neelamkavil, Edison, NJ (US); Nishit Modi, Newark, CA (US); Ashok Bhandari, Pleasanton, CA (US); and Xiaoli Cheng, Mountain View, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE); and Protagonist Therapeutics, Inc., Newark, CA (US)
Filed by Janssen Pharmaceutica NV, Beerse (BE); and Protagonist Therapeutics, Inc., Newark, CA (US)
Filed on Nov. 19, 2021, as Appl. No. 17/531,538.
Claims priority of provisional application 63/275,222, filed on Nov. 3, 2021.
Claims priority of provisional application 63/116,568, filed on Nov. 20, 2020.
Prior Publication US 2022/0177532 A1, Jun. 9, 2022
Int. Cl. C07K 14/47 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 47/69 (2017.01); A61P 37/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/4703 (2013.01) [A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/6923 (2017.08); A61P 37/00 (2018.01); A61K 38/00 (2013.01)] 16 Claims
 
1. A pharmaceutical composition comprising:
a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the pharmaceutical composition; and
one or more pharmaceutically acceptable excipients.